Last week saw a number of broker notes hitting the wires once again. Three buy ratings that caught my eye are summarised below.
Here's why brokers think investors ought to buy them next week:
Healius Ltd (ASX: HLS)
According to a note out of Credit Suisse, its analysts have retained their outperform rating and $4.30 price target on this healthcare company's shares. The broker believes that Healius is well-placed to benefit from increased demand for COVID testing. Combined with a reduction in costs and smart investments, it is expecting strong earnings growth in the near term. The Healius share price ended the week at $3.88.
Nuix Ltd (ASX: NXL)
Analysts at Morgan Stanley have initiated coverage on this investigative analytics and intelligence software provider's shares with an overweight rating and $11.00 price target. The broker believes Nuix is a long term structural growth story with a long runway ahead of it. And although it sees some risks from much larger competitors, that isn't enough to stop it from rating it as a buy at the current level. The Nuix share price last traded at $9.08.
Premier Investments Limited (ASX: PMV)
A note out of the Macquarie equities desk reveals that its analysts have retained their outperform rating and lifted the price target on this retail conglomerate's shares to $28.00. This follows the release of its guidance for the first half, which was significantly higher than the broker was forecasting. In fact, it was more than its estimates for the full year. The positive trends driving this outperformance have led to Macquarie upgrading its earnings estimates for the coming years. The Premier Investments share price ended the week at $24.31.
